Portal de investigación
Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Llombart-Cussac, Antonio
- Fernandez-Murga, Leonor
- Martinez, Eduardo
- Bermejo, Begona
- Rodriguez-Lescure, Alvaro
- Iranzo, Vega
- de la Morena, Pilar
- Iranzo-Barreira, Jorge
- Cortes, Javier
- Riva, Francois
- Perez Garcia, Jose Manuel
- Dustin, Derek
- Vidal-Martinez, Jose
- Marin Liebana, Sara
- Serrano-Garcia, Lucia
- Cejalvo, Juan Miguel
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0732-183X, 1527-7755
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 9,378 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF CLINICAL ONCOLOGY LIPPINCOTT WILLIAMS & WILKINS
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Cita
Llombart,A,Fernandez,L,Martinez,E,Santaballa,A,Bermejo,B,Rodriguez,A,Iranzo,V et al. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2025 p.1052.